

**OPPORTUNITY TO INVEST IN A HEALTHCARE & WELLNESS FAMILY OF COMPANIES
CONSISTING OF: MISSION CRITICAL PHARMACEUTICAL, OTC, CBD, CLINICS &
INDUSTRIAL HEALTH TECH. FOR BOTH HUMAN & ANIMAL.**



**Luminec
Holdings**

**EXECUTIVE SUMMARY
2024**



Improve the body's immune system and help stop death from **COVID-19**. Our product can be useful to attack RNA viruses as well as DNA viruses; successful in treating previous Corona Viruses



IP-rich holding company seeking capital for Rx development and Working Capital with Near-term scale from Nutraceutical / OTC products



Free Amino Ion Theory™ drives the technology platform which includes Triamino™, TAFA400™ With Pharmaceutical Peptides, SK-713™; Unique Delivery Technology for Nutraceuticals & Cosmeceuticals, OTC & RX Formulations. IRT360, CRO-50, X-2, Pharmaceutical Grade-CBD,CBN,CBC & CBG Cannabinoid Nano Water Soluble and clinical services



Key applications: Psoriasis, wound healing, skincare, tumors, diabetes, herpes, auto-immune, digestion, insomnia, anxiety, hormones, blood sepsis, heavy metal toxicity and COPD

**\$35M Series A
Uses: R&D, S&M
Clinic CapEx, WC**


Company Highlights

- Since 2009
- FDA GRAS Status
- Patent(s) Pending
- Retail, OTC, Rx, Clinical Services
- Triamino™/SK-713™ & TAFA400™/SK-713™ : 2,000+ Patients, 900 Animal cases
- 40+ OTC Products for human and animal (10x animal)
- CRO-50 & X-2: 60,000 + Human & Animal Case Studies
- Diversified Revenue Streams
- Manufacturing US – S. America
- Distribution US – S. America (1,200 salesforce)
- Jet Lasik - refractive and corneal therapeutic surgery services and products

Investment Merits

- **A-typical Offering in Biopharma: Company already generating revenue, near-term OTC revenue in scale, and Rx development; diversified rev. stream incl. water treatment**
- **IP Solution Platform has over 100 applications – over 60 human and 30 animal diseases**
- **Serves both Human and Animal markets; agriculture, water treatment on the horizon**
- **OTC Products are natural, FDA GRAS, safer than drinking water**
- **Combined markets served are over \$1 trillion in total opportunity**
- **Management Team and Board includes discipline authorities in Molecular Cell Biology, Organic Chemistry, Medicine, etc.**

Market Opportunity



Company Mission


Platform of Solutions

Our Global Mission:

'To Provide Transformational Healing Products and Services that are Safe, Effective, and Affordable to BOTH Human and Animal.'

...bringing mission critical health & wellness to the entire world – both developed and emerging – by leveraging innovative Intellectual Property, Best-in-Class Management Team and World Class Partners.

- John S. Everding, Co-founder



Retail / OTC Products



Diversified Business Model Linked by Common Core IP



How / Where can I afford to get medical or wellness treatment?



How do I get Prescription Drugs that are affordable, effective and safe?



Where does continued growth, efficiencies and ROI come from?

Retail & OTC Products & Services

- FDA GRAS status
- Peptide technology is alternative to Rx
- 40+ human and animal retail, OTC, cosmetic / beauty / skin products available (10 animal products)
- State-of-the-art medical and wellness clinic with GE Healthcare endorsement
- International distribution with name branding
- Revenues within NTM (next twelve months)

Pharmaceuticals

- Proprietary technologies
- Patents pending
- Live human and animal cases, Lab tests
- Robust potential drug(s) pipeline
- Most pervasive and critical diseases
- Animal and human testing licenses and capabilities

Venture Capital

- Synergistic ingredient technologies
- Incremental R&D assets
- Incremental domain knowledge accretion
- Supply - / value chain benefit
- Financial upside
- Opportunity #1: Redacted.
- Opportunity #2: Redacted.

Competitive Advantages

TRADITIONAL MODEL

LUMINEC DISRUPTIVE MODEL

1

COST & TIME.

FDA NDA process can take up to 12 years and cost \$3 billion per drug. Most prescriptions go unfilled due to prohibitive cost.

2

OVERDOSE, TOXICITIES & ADDICTION.

Global opioid crisis is an epidemic. Occurrences of side-effects and drug addiction are common.

3

SILOS.

Each new drug development process is a unique, new, standalone process without much recyclability.

4

OUTSOURCED R&D MODEL FOR PHARMA DRUGS.

Reliant and vulnerable to inconsistencies, delays IP theft and other conflicts of interest.

1

RETAIL AND OTC PRODUCTS FDA GRAS STATUS.

Affordable and accessible; FDA NDA time process and cost avoided.

2

UNDERLYING TECHNOLOGIES & PROCESS ARE FDA GRAS.

All-natural ingredients and process. Proven safe by testing and live human and animal administration.

3

SCALABILITY.


Common denominator of proprietary technologies have broad applicability to treat wide array of diverse diseases and modalities.

4

COMPLETELY INTEGRATED & ALIGNED R&D LAB CAPABILITIES.

Pharmaceutical R&D Lab is integrated in-house, creating institutional domain, leverageable expertise and inherent scale.

Case Study: Carcinoma Treated with Triamino™



1-19-06



2-12-06



3-12-06



3-23-06



5-26-06

- **LOCALLY ADVANCED BASI-SQUAMOUS CELL CARCINOMA RIGHT INFRAORBITAL SKIN**
- **TREATED WITH TRI-AMINO**
- **CANCER-FREE AFTER 3 MOS.**

Luminec Family of Companies

CORPORATE STRUCTURE



JET LASIK *

Refractive and corneal therapeutic surgery services and products

STRATEGIC PARTNERS / AFFILIATES



VALUE CHAIN PARTNERS



*Luminec is expected to have ownership in Jet Lasik.

Contactation

Christopher Neville, CEO, Luminec Pharmaceuticals
biophotonix@protonmail.com | [+61 433 230 530](tel:+61433230530) (Sydney: GMT+11)

Jet LASIK Profile*


JET LASIK

Dr. Paul H Chen, CEO
1905 Calle Barcelona, #208, Carlsbad, CA 92009


Description: provider of refractive and corneal therapeutic surgery services and products. Creator of Jet Lens™ (Patented), a modified collagen-coated contact lens with a layer of live cultured skin cells.

Background Info: LASIK corrective vision procedure heals quickly but comes with more complications than does the PRK procedure; PRK on the other hand, is safer but it requires separately scheduled procedures for each eye and a longer healing time.

Industry Problem:



Jet Lens Solution:



Profile:

- Incorporated in CA
- IP Portfolio: Patents, Trade Secrets, Trademarks
- Goal: Seeking \$2.5M to fund Master Cell Bank, file for IDE and conduct clinical trials phases 1 – 2; Seeks \$15M to fund phase 3 clinical trial and BLA filing.

Patient Benefits:

- Reduce patient's fear of short / long term complications associated with corneal flaps
- Reduce patient's fear of blurry / painful recovery
- Reduce patient's time off of work

Surgeon Benefits:

- Reduce surgeon's facility opportunity cost associated
- Reduce surgeon's risk of liability
- Marketing "wow" factor

Process:



Better safety and quicker recovery at No Additional Cost



Procedure	Process	Complication	Recovery	Preference
LASIK	Flap	2-5%	1-2 days	Patients
PRK	Cell Removal	1%	1-2 weeks	Surgeons
PRK + JET Lens™	Cell Transplant	<1%?	1-2 days	Both

Unit Level Economics

- COGS (fully loaded)
 - Lens + collagen + cells + glue = \$68 [at current retail]
 - Apligraf™ comparable 75 mm circle @ \$1,000 [SEC filings, by area] = \$50
- Distribution (FedEx) = \$10-25 per lens
- Cost = \$78 - \$93
- Projected retail = \$250-\$350 per lens
- **Gross profit margin** **68-76%**

*Luminec is expected to have ownership in Jet LASIK.